14 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
N=88)
Parkinson Patient Value
(% of total, N=25)
Gender
Female
Male
Age
Average (SD)
Median
Range
Ethnicity
Hispanic or Latino
Not Hispanic
POS AM
vyxw71gp87swa1ijvt0
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-99.1
wedxj
16 Sep 22
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
i1xhjy3f rw
15 Aug 22
Regulation FD Disclosure
5:12pm
8-K
EX-99.1
i46i 2vy2j
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
t2t kymqdrj
24 Mar 22
Regulation FD Disclosure
9:17am
8-K
EX-99.1
3uuzyyznm5trp37bk
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
5ristv ek1
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
5fa9q
17 Aug 21
Regulation FD Disclosure
5:02pm
- Prev
- 1
- Next